Reliable change indices for the Italian version of the Montreal Cognitive Assessment (MoCA) in non-demented Parkinson’s disease patients
Edoardo Nicolò Aiello,
Federica Solca,
Silvia Torre,
Beatrice Curti,
Giulia De Luca,
Ruggero Bonetti,
Francesco Scheveger,
Eleonora Colombo,
Alessio Maranzano,
Marco Olivero,
Claudia Morelli,
Alberto Doretti,
Luca Maderna,
Federico Verde,
Roberta Ferrucci,
Sergio Barbieri,
Fabiana Ruggiero,
Denise Mellace,
Angelica Marfoli,
Angelica De Sandi,
Alberto Priori,
Gabriella Pravettoni,
Vincenzo Silani,
Nicola Ticozzi,
Andrea Ciammola,
Barbara Poletti
Affiliations
Edoardo Nicolò Aiello
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Federica Solca
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Silvia Torre
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Beatrice Curti
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Giulia De Luca
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Ruggero Bonetti
Neurology Residency Program, Università degli Studi di Milano
Francesco Scheveger
Neurology Residency Program, Università degli Studi di Milano
Eleonora Colombo
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Alessio Maranzano
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Marco Olivero
Neurology Residency Program, Università degli Studi di Milano
Claudia Morelli
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Alberto Doretti
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Luca Maderna
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Federico Verde
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Roberta Ferrucci
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano
Sergio Barbieri
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Fabiana Ruggiero
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Denise Mellace
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano
Angelica Marfoli
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano
Angelica De Sandi
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Alberto Priori
“Aldo Ravelli” Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, International Medical School, University of Milan
Gabriella Pravettoni
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano
Vincenzo Silani
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Nicola Ticozzi
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Andrea Ciammola
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Barbara Poletti
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano
Abstract Background . The present study aimed at deriving regression-based reliable change indices (RCIs) for the Montreal Cognitive Assessment (MoCA) in an Italian cohort of non-demented Parkinson’s disease (PD) patients. Methods N = 33 consecutive, non-demented PD patients were followed-up at a 5-to-8-month interval (M = 6.6; SD = 0.6) with the MoCA. Practice effects and test-retest reliability were assessed via dependent-sample t-tests and intra-class correlation (ICC) coefficients, respectively. RCIs were derived separately for raw and demographically adjusted MoCA scores according to a standardized regression-based approach by accounting for both baseline confounders (i.e., demographics, disease duration and Unified Parkinson’s Disease Rating Scale scores) and retest interval. Results No practice effects were found (t(32) = 0.29; p = .778), with acceptable test-retest reliability being detected (ICC = 0.67). MoCA scores at T0 proved to be the only significant predictor of T1 MoCA performances within both the model addressing raw scores and that addressing adjusted scores (ps < 0.001). Conclusions The present study provides Italian practitioners and researchers with regression-based RCIs for the MoCA in non-demented PD patients, which can be reliably adopted for retest interval ≥ 5 and ≤ 8 months without encountering any practice effect.